Prior Immunotherapy May Increase Pneumonitis Risk
Patients with urothelial carcinoma should discuss their prior treatment history with their oncologist.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Would you adjust your medical treatment plan based on new, specific clinical research findings?
A recent study of 315 patients with metastatic urothelial carcinoma found that prior immune checkpoint inhibitor therapy is a risk factor for developing pneumonitis when treated with enfortumab vedotin plus pembrolizumab. Patients receiving this combination therapy should be aware of this potential side effect.
Why it matters
Identifying specific risk factors for pneumonitis helps patients and their care teams better monitor for lung complications during treatment. This insight is especially relevant for those who have already undergone immunotherapy, as it may influence clinical monitoring strategies.
In a retrospective cohort study of 315 patients with locally advanced or metastatic urothelial carcinoma, 7.0% developed pneumonitis. Researchers observed a median time to onset of 77 days, with nearly half of those affected experiencing Grade 3 or worse severity.
The players
The Oncologist
A peer-reviewed medical journal that publishes research on cancer treatment and clinical oncology.
The details
The study examined patients receiving the combination of enfortumab vedotin and pembrolizumab. Pneumonitis is an inflammatory condition of the lungs that can occur during cancer treatment, often requiring intervention with systemic corticosteroids, as seen in 12 of the 22 affected patients in this study. Researchers identified that prior exposure to immune checkpoint inhibitors acts as an independent risk factor for this complication in this specific patient population.
Timeline
October 2026: Study findings published in The Oncologist.
Health Landscape
This study refines the safety understanding of current treatment protocols for patients with advanced or metastatic urothelial cancer. It contributes to the evolving data on how combination therapies impact patient outcomes compared to established standards of care.
Patients currently or previously treated with immune checkpoint inhibitors should discuss their medical history with their oncologist before starting new combination therapies. It is worth asking your doctor what respiratory symptoms to monitor for and when to report them during your treatment.
The takeaway
Pneumonitis is a serious, potential side effect that requires vigilance, especially for those with a history of immunotherapy. Always maintain an open dialogue with your medical team about any new or worsening respiratory issues, such as a persistent cough or difficulty breathing.
Further reading
For more on managing cancer care, visit our Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Would you adjust your medical treatment plan based on new, specific clinical research findings?
